Development of a liposomal formulation of a TKI: the active loading of erlotinib.HCl

No abstract is available for this paper.

• Publication year

  2025

• Venue

  bioRxiv

• Publication date

  2025-06-07

• Fields of study

  Biology, Medicine, Materials Science, Chemistry

• Identifiers
  DOI 10.1101/2025.06.06.658400
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Generation and maintenance of kidney and kidney cancer organoids from patient-derived material for drug development and precision oncology

  2024cited by this paper
• Remote loading in liposome: a review of current strategies and recent developments

  2024cited by this paper
• Patient-Derived Organoids as a Promising Tool for Multimodal Management of Sarcomas

  2023cited by this paper
• Liposomal Form of Erlotinib for Local Inhalation Administration and Efficiency of Its Transport to the Lungs.

  2023cited by this paper
• Development of asolectin-based liposomal formulation for controlled and targeted delivery of erlotinib as a model drug for EGFR monotherapy

  2022cited by this paper
• Increasing Cellular Uptake and Permeation of Curcumin Using a Novel Polymer-Surfactant Formulation

  2022cited by this paper
• Co-encapsulated nanoparticles of Erlotinib and Quercetin for targeting lung cancer through nuclear EGFR and PI3K/AKT inhibition.

  2021cited by this paper
• Organoids: A new approach in toxicity testing of nanotherapeutics

  2021cited by this paper
• Formulation development and upscaling of lipid nanocapsules as a drug delivery system for a novel cyclic GMP analogue intended for retinal drug delivery.

  2021cited by this paper
• Efficacy and Safety of Epidermal Growth Factor Receptor (EGFR) Inhibitors Plus Antiangiogenic Agents as First-Line Treatments for Patients With Advanced EGFR-Mutated Non-small Cell Lung Cancer: A Meta-Analysis

  2020cited by this paper
• Dynamic light scattering (DLS) of nanoencapsulated food ingredients

  2020cited by this paper
• The combination of bevacizumab/Avastin and erlotinib/Tarceva is relevant for the treatment of metastatic renal cell carcinoma: the role of a synonymous mutation of the EGFR receptor

  2020cited by this paper
• Erlotinib Hydrochloride

  2020cited by this paper
• Delivery of erlotinib for enhanced cancer treatment: An update review on particulate systems

  2020cited by this paper
• Development and Characterization of the Solvent-Assisted Active Loading Technology (SALT) for Liposomal Loading of Poorly Water-Soluble Compounds

  2019cited by this paper
• The role of liposomes in clinical nanomedicine development. What now? Now what?

  2019cited by this paper
• Development of anti-angiogenic erlotinib liposomal formulation for pulmonary hypertension: a QbD approach

  2019cited by this paper
• What Drives Innovation: The Canadian Touch on Liposomal Therapeutics

  2019cited by this paper
• Comparative studies on the human serum albumin binding of the clinically approved EGFR inhibitors gefitinib, erlotinib, afatinib, osimertinib and the investigational inhibitor KP2187

  2018cited by this paper
• Simultaneous delivery of paclitaxel and erlotinib from dual drug loaded PLGA nanoparticles: Formulation development, thorough optimization and in vitro release

  2018cited by this paper
• Aptamer-Conjugated Chitosan-Anchored Liposomal Complexes for Targeted Delivery of Erlotinib to EGFR-Mutated Lung Cancer Cells

  2017cited by this paper
• Zeta potential: a case study of cationic, anionic, and neutral liposomes

  2017cited by this paper
• Novel therapeutic modalities and drug delivery – erlotinib liposomes modified with galactosylated lipid: in vitro and in vivo investigations

  2017cited by this paper
• Doxorubicin: nanotechnological overviews from bench to bedside.

  2017cited by this paper
• DLS and zeta potential - What they are and what they are not?

  2016cited by this paper
• Choosing the right cell line for renal cell cancer research

  2016cited by this paper
• Kolliphor surfactants affect solubilization and bioavailability of fenofibrate. Studies of in vitro digestion and absorption in rats.

  2015cited by this paper
• Comparison of sorafenib-loaded poly (lactic/glycolic) acid and DPPC liposome nanoparticles in the in vitro treatment of renal cell carcinoma.

  2015cited by this paper
• Preparation of liposomes at large scale using the ethanol injection method: Effect of scale-up and injection devices

  2015cited by this paper
• Influence of cholesterol on liposome stability and on in vitro drug release

  2015cited by this paper
• Kolliphor® HS 15 Micelles for the Delivery of Coenzyme Q10: Preparation, Characterization, and Stability

  2015influential reference
• Physicochemical properties of epidermal growth factor receptor inhibitors and development of a nanoliposomal formulation of gefitinib.

  2012cited by this paper
• Active methods of drug loading into liposomes: recent strategies for stable drug entrapment and increased in vivo activity

  2011cited by this paper
• Vitamin E TPGS coated liposomes enhanced cellular uptake and cytotoxicity of docetaxel in brain cancer cells.

  2011cited by this paper
• Side-Effects of Long-Term Administration of Erlotinib in Patients with Non-small Cell Lung Cancer

  2010cited by this paper
• Doxorubicin conjugated to D-alpha-tocopheryl polyethylene glycol succinate and folic acid as a prodrug for targeted chemotherapy.

  2010cited by this paper
• Microfluidic methods for production of liposomes.

  2009cited by this paper
• WST-1-based cell cytotoxicity assay as a substitute for MTT-based assay for rapid detection of toxigenic Bacillus species using CHO cell line.

  2008cited by this paper
• Erlotinib in cancer treatment.

  2007cited by this paper
• Remote loading of doxorubicin into liposomes driven by a transmembrane phosphate gradient.

  2006cited by this paper
• Effect of the surface charge of liposomes on their uptake by angiogenic tumor vessels

  2003cited by this paper
• 449 PH GRADIENT LOADING OF ANTHRACYCLINES INTO CHOLESTEROL-FREE LIPOSOMES: ENHANCING DRUG LOADING RATES THROUGH USE OF ETHANOL.

  2001cited by this paper

• No citing papers are available for this paper.